In a trial, Gossamer Bio's PAH treatment candidate seralutinib reduced the resistance blood faces moving into the lungs over ...
Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...
Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback